Reports to the Committee on Safety of Medicines show that skin reactions are the commonest adverse reaction to trimethoprim; the committee has had a few reports of cholestatic jaundice due to trimethoprim and to trimethoprim-sulphamethoxazole. Manufacturers of trimethoprim (Duphar) have received four reports of hepatic reactions: hepatitis (two), jaundice (one), and cholestatic jaundice (one). In previous reports similar hepatic reactions to combination antibiotics have been attributed to the sulphonamide component. I suspect that some of these reactions were due to trimethoprim. The mechanism for such cholestasis is obscure as trimethoprim interferes primarily with the metabolism of folic acid. As the reaction occurred late in life in this patient and was clearly related to exposure to the drug it is unlikely to have been any other form of benign cholestasis.
Possible interaction between heparin and a sulphonylurea a cause of prolonged hypoglycaemia?
Glipizide, a second generation sulphonylurea, has pharmacokinetic properties that lessen the risk of hypoglycaemia. Nevertheless, we describe a patient who suffered recurring hypoglycaemia that lasted for four days after a single 5 mg dose of glipizide.
Case report
A 64 year old diabetic man with peripheral vascular disease was found to be hypoglycaemic (blood glucose 1-9 mmol/l (34-2 mg/100 ml)) immediately before an operation for debridement of a foot ulcer. He had been taking glipizide 5 mg daily since diabetes was diagnosed six months before, with fair control (HbA, 10-2% (normal 6-9%)) and without hypoglycaemia. He had had his usual dose and food intake the previous day and had been fasting for 1O½ /2hours. He received 25 g glucose intravenously and then a 5% dextrose intravenous infusion during the brief operation. Four hours later hypoglycaemia recurred, and over the ensuing 68 hours five symptomatic episodes occurred (blood glucose 14-1-8 mmol/l (25 2-32-4 mg/100 ml)) despite continuous infusions of 5% or 10% dextrose 500 ml every four hours and satisfactory eating. The last episode occurred 99 hours after the last dose of glipizide. Five days later glipizide was represcribed, as he was then hyperglycaemic (glucose 13 mmol/l (234-3 mg/ 100 ml)), but after only one dose of 5 mg he had four hypoglycaemic attacks (glucose 1-0-1-8 mmol/l (18-0-32-4 mg/100 ml)) over the next 36 hours, convulsing during one, again despite eating and continuous intravenous infusion of dextrose. Subsequent hyperglycaemia during four months of follow up was controlled by metformin without trouble.
The original diagnosis of diabetes had been confirmed by a glucose tolerance test, the fasting and two hour capillary blood glucose concentrations being 10 mmol/l (180-2 mg/100 ml) and 14 mmol/l (252-3 mg/100 ml) respectively. During one of his hypoglycaemic episodes (glucose 1-4 mmol/l (25-2 mg/100 ml)) plasma insulin and cortisol concentrations were measured. The insulin concentration was causally increased at 429-1 pmol/l (59-8 mU/1), and cortisol concentration was 0 61 tsmol/l (22-1 [tg/100 ml). A repeat measurement of cortisol during another episode was 0-82 [smol/l (29-7 [tg/1100 ml). Concentrations of thyroxine and thyroid stimulating hormone, plasma urea, and creatinine were normal, as were the results of standard liver function tests.
Comment
Glipizide has a short half life (mean four hours) and is metabolised by the liver; its metabolites, which are excreted by the kidneys, are inactive.' It is therefore judged less likely to cause hypoglycaemia in patients with renal impairment and safer to use in the elderly. Prolonged hypoglycaemia of up to 36 hours, however, has been reported in the presence of impaired liver function, treatment with aspirin, or gastroenteritis.2 In our patient there was no recognised precipitating factor. The results of standard tests of liver and kidney function were normal. His food intake in addition to substantial intravenous glucose was adequate. There was also an adequate cortisol response to hypoglycaemia, which was confirmed to be due to hyperinsulinaemia. That this was secondary to glipizide seems evident.
It was difficult to understand why he should suddenly have become sensitive to glipizide after six months of uncomplicated treatment. He had not received any counteracting diabetogenic drug before admission. The only other drugs given to him in hospital were diamorphine and subcutaneous heparin calcium, neither of which have been reported as interacting with sulphonylureas. Sulphonylureas, however, are highly bound to protein,3 and even small doses of heparin decrease indirectly the binding of drugs by increasing free fatty acid concentrations, an effect more pronounced in patients with diabetes.4 Moreover, glipizide may be more susceptible to drug displacement interactions because of its low volume of distribution.5 The heparin, 5000 units every 12 hours, was begun 36 hours before his last (preoperative) glipizide dose and continued during three weeks of postoperative immobility. Despite glipizide's short half life and the expected compensatory rapid elimination of an increased concentration of unbound drug a sufficiently large amount of free glipizide displaced by heparin could possibly have caused the protracted hyperinsulinaemia and hypoglycaemia. Heparin could possibly also have inhibited the metabolism or excretion of glipizide. Oral anticoagulants may potentiate sulphonylureas,' 3 but we are unaware of any reports implicating heparin.
We thank Dr C E McKean, hospital pharmacist, for help in preparing this Carotid artery stenosis exposed by an adverse effect of captopril Captopril is being administered to an increasing number of patients with arterial hypertension. Cerebral complications are rarely reported. We use the short term captopril test to evaluate patients with hypertension. During this test we observed reversible cerebral symptoms in two patients.
Case reports
Arterial blood pressure and heart rate in the supine position are measured before and every 15 minutes for 90 minutes after the administration of captopril 6 25 mg orally. Plasma renin activity is measured before and 90 minutes after the administration of captopril.
Case 1-The patient was a 67 year old woman who had had hypertension for over 35 years. Sympathectomy in 1954 had not had any appreciable effect. The blood pressure was 220/130 mm Hg, decreasing spontaneously to 160/110 mm Hg. She was treated with prazosin 10 mg, atenolol 25 mg, and a combination of hydrochlorothiazide 50 mg and amiloride 5 mg, all twice daily. Plasma renin activity was 95 mU/l (normal 6-60 mU/l), and serum creatinine concentration 128 tmol/l (1-45 mg/100 ml). Renography and computed tomography of the kidneys showed complete lack of renal function on the left side and a contracted kidney. Seventy five minutes after the administration of captopril she became absent, complaining of paraesthesia of both hands and spots before the eyes. The blood pressure had dropped to 100/85 mm Hg, and the heart rate was 100 beats/ min and stable. She regained consciousness within a couple of minutes without any sequelae. Digital subtraction angiography showed stenosis of the internal carotid artery, external carotid artery, and vertebral artery on the right side. This had not been apparent on auscultation of the vessels.
Case 2-This 67 year old man had had ischaemic heart disease since the age of 58. Hypertension had been diagnosed six months previously, and three years previously an aortic prosthesis had been inserted because of intermittent claudication. Blood pressure was 190/120 mm Hg, and he was treated with clonidine 75 [tg twice daily, methyldopa 125 mg thrice daily, and bendrofluazide 5 mg twice daily. Serum creatinine and plasma electrolyte concentrations and clearance of edetic acid labelled with chromium-51 were normal. Catheterisation of the renal veins showed a plasma renin activity of 1000-2000 mU/l on the right
